The largest and longest study of the obesity drug Wegovy has shown people maintain significant weight loss for at least four ...
The largest and longest study of the obesity drug Wegovy has shown people maintain significant weight loss for at least four years, with fewer serious adverse events than those given placebo 'dummy' ...
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount of weight they lose while on the drug, researchers have found.
New research has found weight loss drug Wegovy can produce significant results for at least four years of treatment. The drug has also been found to deliver cardiovascular benefits in overweight ...
Altimmune is developing Pemvidutide, a drug that shows promising results in fat and weight loss. See why Pemvidutide's ...
Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly, and others could support a global market worth an eye-watering $60 billion within the next decade, according to a ...